#United States #Frederick #Biopharma #OneCyte #Kemp Proteins

OneCyte and Kemp Proteins Join Forces in Strategic Partnership

In a notable development in the biopharmaceutical sector, OneCyte, recognized as a leader in high-throughput single-cell analysis and cell line development technologies, has announced a strategic partnership with Kemp Proteins, a trailblazer in protein engineering and expression solutions. This collaboration aims to provide top-tier cell line development services to biopharma companies across the globe.

The synergy of OneCyte and Kemp Proteins brings together the strengths of both companies. OneCyte's proprietary platform enables high-throughput, high-sensitivity, and rapid clone selection, while Kemp Proteins contributes its advanced molecular engineering capabilities, including its unique machine learning-driven platform, PROTiQ™. This integration is set to push the boundaries of what is possible in the development timelines, yield rates, and successful expression of complex and difficult-to-express biologics. This includes non-monoclonal antibody formats and newly emerging therapeutic modalities.

Addressing Critical Industry Challenges

The biopharmaceutical industry faces numerous obstacles in cell line development. Long development cycles, suboptimal yields, and high failure rates plague the advancement of novel and complex molecules, potentially delaying regulatory timetables and slowing the deployment of life-saving therapies into clinical settings. The OneCyte-Kemp partnership aims to overcome these hurdles by integrating predictive in silico design with swift, high-throughput experimental validation.

In their collaborative workflow, amino acid sequences undergo evaluation through Kemp's innovative PROTiQ™ platform to assess developability risks, pinpoint sequence liabilities, and generate structural insights. The optimized candidates that emerge from this process are then paired with OneCyte's high-performance cell line development platform, facilitating the quick identification of elite clones known for their superior productivity.

An exclusive feature of their combined offering is the access to a royalty-free CHO-K1 GS knockout cell line and a transposase-based expression system. This aspect fosters a flexible and efficient development process free from restrictive licensing constraints. The integrated approach uniquely tailors itself to adapt to the changing needs of new therapeutic modalities, ensuring that speed and performance do not have to be compromised.

Leaders in the Field Speak Out

Commenting on this significant partnership, Dr. Konstantinos Tsioris, Co-founder and President of OneCyte, expressed his enthusiasm, stating, "We are thrilled to be working with Kemp to provide industry-leading cell line development services to the biopharma industry. By combining our single-cell technology with Kemp's deep expertise in protein expression, we are confident that we can address the hardest challenges associated with new modalities, delivering faster timelines and industry-leading titers."

Michael Keefe, CEO of Kemp Proteins, echoed this excitement, noting that his company has been at the forefront of protein expression for several years. He stated, "This partnership positions us to extend and strengthen that leadership. OneCyte's class-leading single-cell technology, stacked on top of our molecular design and expression capabilities, will provide a powerful and differentiated solution for our global biopharma customers."

About OneCyte and Kemp Proteins

OneCyte is a dynamic biotechnology company dedicated to transforming the landscape of cell line development through high-throughput single-cell technologies. Their proprietary platform enables rapid and sensitive analysis as well as selection of elite producer cells, significantly accelerating timelines while enhancing productivity and consistency. Through partnerships with biopharmaceutical companies, OneCyte aims to unleash the full potential of next-generation biologics.

On the other hand, Kemp Proteins is recognized as a preeminent provider of protein engineering and expression services, particularly focusing on the development of challenging, complex biologics. They leverage advanced computational tools, including their proprietary PROTiQ™ platform and extensive expertise, to enable the efficient design, optimization, and production of top-quality therapeutic proteins for global biopharmaceutical partners.

As these two industry leaders join forces, they pledge to reshape the biopharma landscape, tackling the toughest challenges in cell line development and setting new standards for efficiency and productivity.